Who are FFP's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Fresh Frozen Plasma (FFP), Fresh frozen plasma, Pathogen-Reduced Plasma, Dry plasma, Fresh frozen plasma transfusion, FS VH S/D 500 s-apr.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ffp.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

FFP — Competitive Intelligence Brief

FFP (FFP) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Blood product / Plasma derivative. Area: Hematology / Hemostasis.

marketed Blood product / Plasma derivative Hematology / Hemostasis Biologic Live · refreshed every 30 min

Target snapshot

FFP (FFP) — Erasmus Medical Center. FFP (Fresh Frozen Plasma) replaces clotting factors and other plasma proteins to restore hemostatic function in patients with coagulation deficiencies.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
FFP TARGET	FFP	Erasmus Medical Center	marketed	Blood product / Plasma derivative
Fresh Frozen Plasma (FFP)	Fresh Frozen Plasma (FFP)	Vascular Solutions LLC	marketed	Blood product / Plasma derivative
Fresh frozen plasma	Fresh frozen plasma	Rigshospitalet, Denmark	marketed	Blood product / Plasma derivative
Pathogen-Reduced Plasma	Pathogen-Reduced Plasma	Coalition for National Trauma Research	marketed	Blood product / Plasma derivative
Dry plasma	Dry plasma	Vastra Gotaland Region	marketed	Blood product / Plasma derivative
Fresh frozen plasma transfusion	Fresh frozen plasma transfusion	Rutgers, The State University of New Jersey	phase 3	Blood product / Plasma derivative
FS VH S/D 500 s-apr	FS VH S/D 500 s-apr	Baxter Healthcare Corporation	phase 3	Blood product / Plasma derivative

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Blood product / Plasma derivative class)

Baxter Healthcare Corporation · 1 drug in this class
Coalition for National Trauma Research · 1 drug in this class
Erasmus Medical Center · 1 drug in this class
Rigshospitalet, Denmark · 1 drug in this class
Rutgers, The State University of New Jersey · 1 drug in this class
Vascular Solutions LLC · 1 drug in this class
Vastra Gotaland Region · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). FFP — Competitive Intelligence Brief. https://druglandscape.com/ci/ffp. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab